Beijing Leadman Biochemistry (300289.SZ) subsidiary's restructured application for clinical trials of B group meningococcal vaccine has been approved.
Lindeman (300289.SZ) announced that it recently received a report from its subsidiary, Beijing Xianshengxiangrui Biological Products Co., Ltd. (referred to as Xianshengxiangrui), stating that the recombinant Group B meningococcal vaccine (Escherichia coli) developed by Xianshengxiangrui has obtained the "Approval Notice for Clinical Trials" from the National Medical Products Administration. The drug will undertake clinical trials for the prevention of epidemic meningitis caused by Group B Neisseria meningitidis.
Beijing Leadman Biochemistry (300289.SZ) announced that it recently received a report from its subsidiary Beijing Xiansheng Xiangrui Biological Products Co., Ltd. (referred to as Xiansheng Xiangrui) stating that the recombinant group B meningococcal vaccine (Escherichia coli) developed by Xiansheng Xiangrui has obtained the "Notice of Approval for Clinical Trials" from the National Medical Products Administration. Clinical trials will be conducted for the prevention of epidemic meningitis caused by group B Neisseria meningitidis.
Related Articles
US Stock Market Move | ZAI LAB (ZLAB.US) surged over 12%, with Q2 product revenue increasing by 11% quarter-on-quarter.
NETJOY (02131) announced its performance for the fiscal year 2025, reporting a loss attributable to equity holders of the parent company of 48.028 million yuan, a year-on-year reduction of 89.55%.
EDDING GENOR (06998): Completion of drug administration for the first subject in the Phase II clinical trial of GB268.
US Stock Market Move | ZAI LAB (ZLAB.US) surged over 12%, with Q2 product revenue increasing by 11% quarter-on-quarter.
NETJOY (02131) announced its performance for the fiscal year 2025, reporting a loss attributable to equity holders of the parent company of 48.028 million yuan, a year-on-year reduction of 89.55%.
EDDING GENOR (06998): Completion of drug administration for the first subject in the Phase II clinical trial of GB268.
RECOMMEND
